Quest Diagnostics Inkomsten in het verleden
Verleden criteriumcontroles 3/6
De winst van Quest Diagnostics is gedaald met een gemiddeld jaarlijks percentage van -5.7%, terwijl de winst van de Healthcare -industrie jaarlijks groeide met 5.4%. De inkomsten zijn groeide met een gemiddeld percentage van 3.1% per jaar. Het rendement op het eigen vermogen Quest Diagnostics bedraagt 12.9% en de nettomarge bedraagt 8.8%.
Belangrijke informatie
-5.7%
Groei van de winst
-1.8%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 8.5% |
| Inkomstengroei | 3.1% |
| Rendement op eigen vermogen | 12.9% |
| Nettomarge | 8.8% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Earnings Update: Quest Diagnostics Incorporated (NYSE:DGX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Oct 25
Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat
Oct 24Why Investors Shouldn't Be Surprised By Quest Diagnostics Incorporated's (NYSE:DGX) P/E
Oct 23Quest Diagnostics: The Better Half Of An Emerging Healthcare Duopoly
Oct 15These 4 Measures Indicate That Quest Diagnostics (NYSE:DGX) Is Using Debt Reasonably Well
Aug 30Should You Think About Buying Quest Diagnostics Incorporated (NYSE:DGX) Now?
Aug 12Quest Diagnostics: Beat Down After Beating Q2 Estimates
Jul 28The Price Is Right For Quest Diagnostics Incorporated (NYSE:DGX)
Jul 12Quest Diagnostics: On A Quest For Growth
Jul 12Quest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its Returns
May 14Quest Diagnostics: Let's Keep Waiting
May 08Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Apr 26We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt
Apr 23Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares
Apr 02Quest Diagnostics (NYSE:DGX) Is Paying Out A Larger Dividend Than Last Year
Mar 15Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.75
Feb 06Quest Diagnostics: Post-COVID Normalization Pretty Much Done
Feb 05Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly
Jan 11Why We're Not Concerned About Quest Diagnostics Incorporated's (NYSE:DGX) Share Price
Dec 24Quest Diagnostics: Market Overreaction Creates Investment Opportunity
Dec 08Is There Now An Opportunity In Quest Diagnostics Incorporated (NYSE:DGX)?
Dec 06Quest Diagnostics' (NYSE:DGX) Returns Have Hit A Wall
Nov 18Quest Diagnostics: Moving Past Covid
Oct 25Here's Why Quest Diagnostics (NYSE:DGX) Can Manage Its Debt Responsibly
Sep 25What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Sep 04Quest Diagnostics: Q2 Earnings Reveal Promising Growth Trends Despite Dwindling COVID Testing Revenues
Aug 15Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
Aug 13Quest Diagnostics Incorporated (NYSE:DGX) Shares Could Be 46% Below Their Intrinsic Value Estimate
Jul 11Is Quest Diagnostics (NYSE:DGX) A Risky Investment?
Jun 09Quest Diagnostics: Healthier Diagnosis
May 30Is It Time To Consider Buying Quest Diagnostics Incorporated (NYSE:DGX)?
May 24Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
May 09An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 24% Undervalued
Mar 22What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Feb 19Why Quest Diagnostics Isn't A 'Buy', My Oh My
Feb 14Quest Diagnostics' (NYSE:DGX) Upcoming Dividend Will Be Larger Than Last Year's
Feb 05Opbrengsten en kosten
Opbrengsten en kosten
Hoe Quest Diagnostics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 9,539 | 838 | 1,681 | 0 |
| 30 Jun 24 | 9,346 | 836 | 1,624 | 0 |
| 31 Mar 24 | 9,287 | 842 | 1,621 | 0 |
| 31 Dec 23 | 9,252 | 850 | 1,615 | 0 |
| 30 Sep 23 | 9,297 | 759 | 1,748 | 0 |
| 30 Jun 23 | 9,488 | 790 | 1,825 | 0 |
| 31 Mar 23 | 9,603 | 789 | 1,832 | 0 |
| 31 Dec 22 | 9,883 | 942 | 1,818 | 0 |
| 30 Sep 22 | 10,294 | 1,230 | 1,736 | 0 |
| 30 Jun 22 | 10,582 | 1,479 | 1,705 | 0 |
| 31 Mar 22 | 10,679 | 1,874 | 1,715 | 0 |
| 31 Dec 21 | 10,788 | 1,988 | 1,723 | 0 |
| 30 Sep 21 | 11,046 | 2,175 | 1,674 | 0 |
| 30 Jun 21 | 11,058 | 2,238 | 1,642 | 0 |
| 31 Mar 21 | 10,335 | 1,794 | 1,571 | 0 |
| 31 Dec 20 | 9,437 | 1,425 | 1,545 | 0 |
| 30 Sep 20 | 8,361 | 1,101 | 1,414 | 0 |
| 30 Jun 20 | 7,531 | 749 | 1,378 | 0 |
| 31 Mar 20 | 7,657 | 771 | 1,376 | 0 |
| 31 Dec 19 | 7,726 | 835 | 1,457 | 0 |
| 30 Sep 19 | 7,639 | 709 | 1,402 | 0 |
| 30 Jun 19 | 7,572 | 707 | 1,406 | 0 |
| 31 Mar 19 | 7,538 | 720 | 1,387 | 0 |
| 31 Dec 18 | 7,531 | 733 | 1,395 | 0 |
| 30 Sep 18 | 7,557 | 860 | 1,378 | 0 |
| 30 Jun 18 | 7,524 | 808 | 1,359 | 0 |
| 31 Mar 18 | 7,469 | 782 | 1,372 | 0 |
| 31 Dec 17 | 7,402 | 769 | 1,421 | 0 |
| 30 Sep 17 | 7,398 | 671 | 1,413 | 0 |
| 30 Jun 17 | 7,427 | 701 | 1,480 | 0 |
| 31 Mar 17 | 7,469 | 702 | 1,558 | 0 |
| 31 Dec 16 | 7,214 | 642 | 1,337 | 0 |
| 30 Sep 16 | 7,503 | 675 | 1,624 | 0 |
| 30 Jun 16 | 7,498 | 825 | 1,637 | 0 |
| 31 Mar 16 | 7,517 | 748 | 1,637 | 0 |
| 31 Dec 15 | 7,493 | 706 | 1,616 | 0 |
| 30 Sep 15 | 7,527 | 703 | 1,654 | 0 |
| 30 Jun 15 | 7,551 | 491 | 1,657 | 0 |
| 31 Mar 15 | 7,528 | 507 | 1,651 | 0 |
| 31 Dec 14 | 7,435 | 549 | 1,635 | 0 |
| 30 Sep 14 | 7,308 | 506 | 1,638 | 0 |
| 30 Jun 14 | 7,192 | 780 | 1,620 | 0 |
| 31 Mar 14 | 7,105 | 799 | 1,620 | 0 |
| 31 Dec 13 | 7,146 | 811 | 1,632 | 0 |
Kwaliteitswinsten: DGX heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (8.8%) DGX } zijn hoger dan vorig jaar (8.2%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van DGX is de afgelopen 5 jaar met 5.7% per jaar gedaald.
Versnelling van de groei: De winstgroei van DGX over het afgelopen jaar ( 10.4% ) overtreft het 5-jarig gemiddelde ( -5.7% per jaar).
Winst versus industrie: De winstgroei DGX over het afgelopen jaar ( 10.4% ) overtrof de Healthcare -sector 11.4%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 12.9% ) van DGX wordt als laag beschouwd.